Stock Analysis
- Sweden
- /
- Medical Equipment
- /
- NGM:REDS
Redsense Medical Full Year 2023 Earnings: kr0.32 loss per share (vs kr0.62 loss in FY 2022)
Redsense Medical (NGM:REDS) Full Year 2023 Results
Key Financial Results
- Revenue: kr25.6m (up 53% from FY 2022).
- Net loss: kr4.51m (loss narrowed by 49% from FY 2022).
- kr0.32 loss per share (improved from kr0.62 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Redsense Medical shares are up 1.2% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 5 warning signs for Redsense Medical (3 are a bit concerning) you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether Redsense Medical is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NGM:REDS
Redsense Medical
Redsense Medical AB (publ) develops, markets, and sells monitoring systems for medical treatments primarily in Europe and the United States.
Excellent balance sheet and overvalued.